Indeed, there are other important oncogenic pathways in colon cancer, such as WNT and EGFR [84,85], which interfere with the efficacy of KRAS (G12C) blockade, and KRAS inhibition alone does not appear to be sufficient to impede the oncogenic process [86]. This evidence concerns the gene KRAS and malignant colon neoplasm.